Benefits of Genetic Technologies, Agricultural, Medical and Industrial Uses
You'll be able to evaluate domain-specific benefits with accurate examples.
In November 2018, researcher He Jiankui announced at the Hong Kong International Human Gene Editing Summit that he had used CRISPR to edit the CCR5 gene in human embryos; two girls ('Lulu' and 'Nana') were born with edited germlines. He was sentenced to 3 years imprisonment in China in 2019. WHO convened its International Commission on Human Germline Genome Editing in response. This lesson evaluates genetic technologies by domain, and He Jiankui's case is the most direct test of those frameworks.
Connect benefits to evidence
Test an absolute claim before building a balanced evaluation.
Three quick questions from earlier lessons. Pulling old material back to mind before you learn something new makes the new material stick better, so this is not busywork.
Practise this lesson
Four printable worksheets that build from the foundations up to exam-style questions, start at whatever level suits you.
Benefits of genetic technologies across agricultural, medical and industrial domains.
A student says, "Genetic technologies are obviously beneficial because they improve productivity, so there is no real downside worth mentioning."
Before reading on, explain why that claim is too weak. What else must be considered, especially in agricultural applications?
Know
- Genetic technologies can provide benefits in agriculture, medicine and industry.
- Agricultural benefits can include yield, resistance and nutritional modification.
- Medical and industrial uses often involve biological production systems.
Understand
- Benefits depend on the application domain and the comparison being made.
- Agricultural benefit is not automatically the same as biodiversity benefit.
- Strong evaluation includes both usefulness and trade-offs.
Apply
- Evaluate domain-specific benefits with accurate examples.
- Explain biodiversity trade-offs in agricultural biotechnology.
- Use balanced language rather than one-sided claims.
Core Content
Explain how benefits are judged
Define the comparator, beneficiaries and evidence needed for evaluation.
Evaluative frame · "beneficial for whom, vs what?"
He Jiankui's 2018 CRISPR edit of human embryos aimed at a genuine medical benefit: CCR5 deletion is associated with HIV resistance, and the children were born to an HIV-positive father. Yet the global scientific community condemned the work. By contrast, recombinant insulin (Humulin, FDA-approved 1982) is widely accepted as beneficial. The difference is not technology type, both used genetic modification. The difference is consent, germline heritability, risk-benefit proportionality, and whether the individuals most affected had agency in the decision.
In HSC responses, the strongest evaluation asks what kind of benefit is being discussed. Higher crop output is an agricultural benefit. Greater access to useful medicines is a medical benefit. Lower-cost or more efficient biological manufacturing is an industrial benefit. Those are not the same claim, so they should not be collapsed into one vague statement.
Evaluating a genetic technology as "beneficial" requires specifying domain (agricultural/medical/industrial), for whom, and compared with what alternative, generic claims such as "it helps people" are insufficient for HSC evaluation.
Pause, copy the highlighted evaluative requirement into your book before moving on.
"Genetic technologies are beneficial because they help people" is a strong, complete HSC evaluation.
Genetically modified bacteria are used to produce human insulin for treating diabetes.
Genetic technologies have no applications in environmental conservation or bioremediation.
Represent agricultural benefits
Connect engineered traits to yield, resistance, nutrition and trade-offs.
Application domain · the most trade-off-heavy
We just saw that claims about benefit must be tied to a specific domain and comparison. That raises a question: what does evaluation look like for agricultural biotechnology specifically? This card answers it → agricultural benefits and biodiversity trade-offs.
Yield and productivity
Genetic technologies can support greater output by improving how successfully crops or livestock perform under given conditions.
Resistance traits
Useful traits such as pest resistance can reduce damage and improve reliability of production.
Nutritional modification
Food organisms may be modified to improve their nutritional profile, supporting food quality as well as quantity.
These are real benefits because they can improve food production, reduce losses and sometimes improve food quality. But a strong answer must not stop at productivity. Agriculture is the domain where biodiversity trade-offs become especially important.
Agricultural benefits include improved yield, resistance traits and nutritional modification, but agricultural biotechnology also carries the strongest biodiversity trade-offs, reliance on a narrow range of successful genotypes can reduce genetic diversity and lower resilience.
Add the highlighted point to your notes before the check below.
Which is an agricultural benefit of genetic technologies?
Respond with medical evidence
Use recombinant insulin and genetic testing as concrete examples.
Application domain · controlled biological production
We just saw that agricultural benefits come with biodiversity trade-offs. That raises a question: how are medical benefits both similar and different? This card answers it → medical biotechnology and controlled biological production.
Useful protein production
Genetic technologies can support production of medically important molecules such as insulin.
Controlled biological systems
Host cells can be used as reliable biological producers, improving scale and consistency of medical products.
Treatment support
Recombinant microbes can produce human insulin, while genetic tests can identify variants that guide diagnosis or treatment.
The key medical idea is usefulness through controlled production and targeted biological effect. This is why gene cloning and recombinant DNA technology matter beyond the laboratory: they support actual medical application.
Medical benefits centre on controlled biological production of useful proteins (e.g. insulin) and targeted treatment support, the key idea is usefulness through controlled production, which is why gene cloning and recombinant DNA matter beyond the laboratory.
Pause, write the highlighted principle into your book.
Which is the clearest medical application of genetic technologies in this syllabus context?
Evaluate across domains
Compare industrial applications and biodiversity trade-offs.
Application domain · same logic as medicine
We just saw that medical benefits come from controlled biological production of useful proteins. That raises a question: how does industrial biotechnology follow the same logic? This card answers it → industrial enzymes and biological manufacturing.
Industrial enzymes
Genetic technologies can help produce useful enzymes that support industrial processing.
Biological manufacturing
Cells and organisms can be used to manufacture useful compounds at scale more efficiently.
Consistency and scale
Controlled biological systems allow reliable repeated production for industrial use.
Industrial application is often the least intuitive for students, but it follows the same logic as medicine: once a biological system can be directed to make a useful product, it can become part of a manufacturing process.
Industrial benefits include enzyme production and biological manufacturing at scale, this follows the same logic as medicine: once a biological system can be directed to make a useful product, it becomes part of a manufacturing process, not just a research tool.
Pause, copy the highlighted comparison into your notes before continuing.
Which example best fits an industrial application?
Agricultural evaluation · the high-yield judgement
We just saw that industrial biotechnology shares production logic with medical biotechnology. That raises a question: how should the biodiversity trade-off in agriculture be addressed in a final evaluation? This card answers it → balancing agricultural benefit against biodiversity risk.
Agricultural biotechnology may improve yield, resistance or nutrition, but it can also reduce diversity if systems become dominated by a narrow range of genotypes. This matters because biodiversity is linked to resilience, not just immediate output.
Possible benefit
- Improved crop performance.
- Reduced pest damage.
- Higher or more reliable production.
Possible trade-off
- Narrower genetic diversity.
- Greater reliance on a few successful genotypes.
- Lower resilience if conditions change or disease spreads.
Strong judgement style
- State the benefit clearly.
- Name the biodiversity risk clearly.
- Conclude with conditional, balanced language.
Agricultural benefit does not cancel biodiversity trade-offs, reliance on a few successful genotypes reduces diversity, and lower diversity reduces resilience; the strongest HSC judgement states the benefit, names the biodiversity risk, and ends with conditional, balanced language.
Pause, write the highlighted evaluative principle into your book.
Biodiversity matters because it is linked to _____, the ability to cope with change, not just immediate output.
Activities
Apply a balanced judgement
Classify benefits and write a conditional evaluation.
Sort the Benefits
Sort each benefit into its main domain (agriculture, medicine or industry): improved pest resistance, insulin production, industrial enzyme manufacture, nutritional modification of a food crop.
Build the Judgement
Write a balanced judgement about a pest-resistant transgenic crop that states a clear benefit, names a biodiversity trade-off, and ends with conditional language.
Domain-specific benefit
- Agriculture: yield, resistance, nutritional modification. Medicine: production of useful biological products. Industry: enzyme use and biological manufacturing.
Agricultural trade-off
- Agricultural benefit ≠ biodiversity benefit. Reliance on a narrow range of genotypes can reduce genetic diversity and resilience.
Evaluative conclusion
- Genetic technologies can be highly beneficial, but the type and extent of benefit depend on the application and must be weighed against trade-offs, especially biodiversity trade-offs in agriculture.
Common exam error
- Confusing productivity gain with biodiversity gain.
Evaluate the benefits of using genetic technologies across agricultural, medical and industrial applications.
Evaluate is this dot point's own verb, and the dot point names three fields. A judgement that treats them as one will be wrong about at least two, because the benefit differs in kind between them.
Plan: state the criteria, judge each field against them, reach a verdict comparing the three, then qualify it.
Benefit will be judged in each field on how well evidenced it is, whether an alternative could deliver the same result, and who receives it.
The industrial benefit is the best evidenced and the least contested. Enzymes produced by modified microorganisms replace harsher chemical processes in detergents, textiles and food manufacture, operating at lower temperatures and producing less waste, and recombinant enzymes are cheaper and more consistent than extracting them from animal tissue — chymosin for cheesemaking being the standard example. The alternative here is worse on both cost and environmental impact, so the benefit is clear.
The medical benefit is large but unevenly distributed. Recombinant insulin, human growth hormone and clotting factors replaced animal-derived or donor-derived products that were limited in supply and carried infection risk, which is a benefit no alternative could match. Gene therapies treat a small number of previously untreatable conditions but at costs that place them out of reach for most of the world, so the benefit is real and its distribution is narrow.
The agricultural benefit is the largest in scale and the most contested. Insect-resistant and herbicide-tolerant crops have raised yields and altered pesticide use over very large areas, but conventional breeding offers a partial alternative for many traits, and the benefits accrue substantially to seed suppliers as well as growers. Here the criteria pull against each other rather than agreeing.
The benefits are clearest where the technology does something no alternative can and where the product is cheap to distribute. On that basis the industrial and pharmaceutical-manufacturing applications are the strongest, medical therapy is strong in effect and weak in reach, and agriculture is large in scale but the most dependent on how the benefit is shared. Benefit therefore tracks irreplaceability and distribution rather than the sophistication of the technology.
The qualification is that these fields are not independent. The techniques that make industrial enzyme production routine were developed for medical products, and agricultural genomics now feeds back into both — so evaluating any one field in isolation understates the benefit of the others.
Benefit will be judged in each field on how well evidenced it is, whether an alternative could deliver the same result, and who receives it. The industrial benefit is best evidenced and least contested: enzymes from modified microorganisms replace harsher chemical processes in detergents, textiles and food manufacture at lower temperatures with less waste, and recombinant enzymes such as chymosin for cheesemaking are cheaper and more consistent than animal-extracted equivalents, so the alternative is worse on both cost and environmental impact. The medical benefit is large but unevenly distributed — recombinant insulin, growth hormone and clotting factors replaced animal- or donor-derived products limited in supply and carrying infection risk, a benefit no alternative could match, while gene therapies treat a small number of previously untreatable conditions at costs beyond reach for most of the world. The agricultural benefit is largest in scale and most contested, since insect-resistant and herbicide-tolerant crops have raised yields and changed pesticide use over vast areas, but conventional breeding is a partial alternative for many traits and the benefit accrues substantially to seed suppliers as well as growers, so here the criteria pull against each other. Benefits are therefore clearest where the technology does what no alternative can and the product is cheap to distribute: industrial and pharmaceutical manufacturing are strongest, medical therapy is strong in effect and weak in reach, and agriculture is large in scale but most dependent on how the benefit is shared — so benefit tracks irreplaceability and distribution rather than technological sophistication. The qualification is that the fields are not independent, since the techniques making industrial enzyme production routine were developed for medical products and agricultural genomics now feeds back into both, so evaluating one in isolation understates the others.
Justify the use of genetically modified bacteria rather than animal extraction as the source of human insulin.
Justify means support a decision with evidence and reasoning. The decision is given, so the answer must argue for it — while still acknowledging what the alternative offered, or the justification is unsupported assertion.
Plan: state the decision and the criteria it should be judged on, give the supporting reasons in order of strength, address the alternative, then conclude.
The decision to produce insulin from modified bacteria rather than extract it from pig and cattle pancreases is justified on three grounds: the identity of the product, the security of supply, and the ethical and practical cost of the alternative.
Animal insulin differs from human insulin in its amino acid sequence — porcine by one residue, bovine by three — and those differences are enough for some patients' immune systems to recognise it as foreign, producing antibodies that reduce its effect and cause reactions. A bacterium carrying the human gene produces the human sequence exactly, so the immunological problem is removed at its source rather than managed.
Extraction required large quantities of pancreatic tissue, so supply was tied to meat production and could not be increased in response to rising diabetes prevalence. Bacterial culture scales with fermenter capacity, and because the bacteria divide rapidly the quantity produced is limited by manufacturing decisions rather than by an external industry — which is what made universal access to insulin practical.
A product from a defined bacterial culture can be purified to a consistent standard and carries no risk of transmitting an animal pathogen, whereas tissue-derived preparations varied between batches and carried contamination risk. The bacterial route also avoids the use of animal tissue entirely, which is an ethical advantage independent of the clinical ones.
Animal insulin was not without merit: it was effective for the majority of patients for sixty years, and a small number reported better symptom awareness on it than on the recombinant product. But those advantages applied to some patients rather than to supply as a whole, and none of them addressed the scale problem — so they qualify the decision without undermining it.
The decision to produce insulin from modified bacteria rather than extract it from pig and cattle pancreases is justified on the identity of the product, the security of supply, and the cost of the alternative. Animal insulin differs from human insulin in its amino acid sequence, porcine by one residue and bovine by three, and those differences are enough for some patients' immune systems to recognise it as foreign, producing antibodies that reduce its effect and cause reactions — whereas a bacterium carrying the human gene produces the human sequence exactly, removing the immunological problem at source rather than managing it. Extraction also required large quantities of pancreatic tissue, so supply was tied to meat production and could not rise in response to increasing diabetes prevalence, while bacterial culture scales with fermenter capacity and the organisms divide rapidly, so output is limited by manufacturing decisions rather than by an external industry — which is what made universal access practical. A product from a defined bacterial culture can be purified to a consistent standard and carries no risk of transmitting an animal pathogen, unlike tissue-derived preparations that varied between batches, and the bacterial route avoids animal tissue entirely, an ethical advantage independent of the clinical ones. Animal insulin was not without merit — it was effective for most patients for sixty years and some reported better symptom awareness on it — but those advantages applied to particular patients rather than to supply as a whole and none addressed the scale problem, so they qualify the decision without undermining it.
Practise the lesson
Answer fresh questions, explain your reasoning and compare model responses.
A fresh set drawn from this lesson's question bank, feedback shown immediately. +5 XP per correct · +25 XP all correct
Pick your answer, then rate your confidence, that tells the system what to drill next.
UnderstandBand 3(3 marks) 1. Outline one agricultural benefit and one medical benefit of genetic technologies.
AnalyseBand 4(4 marks) 2. Explain why agricultural benefits of genetic technologies should be evaluated alongside biodiversity trade-offs.
EvaluateBand 5–6(5 marks) 3. Evaluate the statement: "Genetic technologies are beneficial mainly because they increase efficiency."
Show all answers
Multiple choice
MC answers and full explanations are shown inline as you complete each question. Use the retry button to attempt a fresh set from the lesson bank.
Activity 1, Sort the benefits
Improved pest resistance and nutritional modification belong mainly to agriculture. Insulin production belongs mainly to medicine. Industrial enzyme manufacture belongs mainly to industry. The key idea is that benefit must be tied to the domain where it operates.
Activity 2, Build the judgement
A strong answer would say that the crop may be beneficial because it improves yield or pest resistance, but that biodiversity trade-offs must also be considered if agriculture becomes dominated by a narrow range of genotypes. The final judgement should be conditional rather than absolute.
Short Answer Model Responses
Q1 (3 marks): One agricultural benefit is improved crop performance, such as better yield or pest resistance [1]. One medical benefit is production of useful biological products such as insulin [1]. These show that benefits differ depending on the application domain [1].
Q2 (4 marks): Agricultural benefits of genetic technologies can include higher yield, resistance to pests and improved food quality [1]. However, agricultural systems may also become more genetically uniform if reliance on a narrow range of successful genotypes increases [1]. Reduced diversity can lower resilience and create biodiversity trade-offs [1]. Therefore agricultural benefit should be evaluated alongside biodiversity rather than being judged by productivity alone [1].
Q3 (5 marks): Efficiency is important because genetic technologies can improve production and make useful outcomes more reliable [1]. However, benefits are broader than efficiency alone because they include medical protein production, industrial enzyme manufacture and nutritional improvement in food systems [1]. In agriculture especially, trade-offs such as reduced diversity may also matter [1]. Therefore the statement is partly correct, but too narrow [1]. Genetic technologies are beneficial in multiple ways and should be evaluated by domain, evidence and trade-offs rather than by efficiency alone [1].
Review and reflect
Retrieve the big ideas, test your fluency and revisit your opening claim.
Agriculture
Yield, resistance and nutritional modification can be genuine benefits.
Medicine
Recombinant insulin and genetically informed diagnosis are concrete medical benefits.
Industry
Enzymes and biological manufacturing matter at scale.
Exam trap
Confusing productivity gain with biodiversity gain.
Rapid-fire questions on agricultural, medical and industrial benefits and biodiversity trade-offs. Beat the boss to bank a tier, gold (perfect + fast), silver (80%+), or bronze (cleared).
Return to He Jiankui's 2018 announcement at the Hong Kong Human Gene Editing Summit and his subsequent 2019 imprisonment. You should now be able to explain that the world's condemnation of He Jiankui's work, despite a genuine medical rationale (CCR5/HIV resistance), reflects the key ethical principles that apply to all germline genetic technologies: the edited children ('Lulu' and 'Nana') could not consent; the germline edits will be inherited by their own children indefinitely; and off-target CRISPR effects were not fully characterised before implantation. These principles apply equally to agricultural and industrial genetic technologies, benefit always depends on domain, consent, reversibility, and evidence quality.